Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir plus hydroxychloroquine versus hydroxychloroquine alone for COVID-19 pneumonia
IRCT20200421047155N1Phase 3Completed
- Sponsor
- Ardabil University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia comparing Tenofovir + hydroxychloroquine with Hydroxychloroquine alone (2 arms). Primary endpoints: Alleviation of symptoms, recovery, and discharge, Deterioration of symptoms transfer to ICU and 1 more. Started Apr 2020; status: completed.
02
Drugs
tenofovirhydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20200421047155N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200421047155N1.